GGrantIndex
Sort

23,748 grants matching melanoma

Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer

$519,704
Noriyuki Kasahara · University Of California, San Francisco · R01 · FY2022 · CA

Defining the role of mitochondrial injury in MEK inhibitor cardiotoxicity

$519,681
Brian C Jensen · Univ Of North Carolina Chapel Hill · R01 · FY2025 · HL

Mouse Resource Core

$519,574
Edward A Clark · University Of Washington · U19 · FY2017 · AI

Regulation of Ras-Dependent Signal Transduction Pathways

$519,504
Deborah K Morrison · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies

$519,480
Lee Roy Morgan · Dekk-Tec, Inc. · R44 · FY2019 · CA

STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma

$519,464
Jinming Gao · Ut Southwestern Medical Center · U01 · FY2019 · CA

Immunotherapeutic Nanoparticle Delivery to Melanoma With MR-Guided Focused Ultrasound

$519,263
Richard J Price · University Of Virginia · R01 · FY2017 · CA

MITF from control of pigmentation to melanoma risk

$519,228
David E Fisher · Massachusetts General Hospital · R01 · FY2024 · AR

Sleep and Cancer: Evaluation of Risk and Insights into Mechanisms

$519,202
Peggy Reynolds · University Of California, San Francisco · R01 · FY2020 · CA

A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously

$519,100
Lawrence Kwong · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA

Generation of T-cell receptors recognizing antigens on non-melanoma tumors

$518,832
James C Yang · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA

CDKN2A couples lipid metabolism to ferroptosis in glioblastoma

$518,756
David A. Nathanson · University Of California Los Angeles · R01 · FY2022 · NS

NCI National Clinical Trials Network – Network Lead Academic Participating Site

$518,725
Lawrence E Flaherty · Wayne State University · UG1 · FY2022 · CA

Microbiota-Immune Interactions in CTLA-4 Antibody Blockade-Induced Colitis

$518,680
Gabriel Nunez · University Of Michigan At Ann Arbor · R01 · FY2025 · DK

Targeting Hippo pathway in melanoma

$518,652
Xu Wu · Massachusetts General Hospital · R01 · FY2022 · CA

Targeting Hippo pathway in melanoma

$518,652
Xu Wu · Massachusetts General Hospital · R01 · FY2023 · CA

Harnessing NKT Cell Activation by Glycolipids

$518,569
Amy R. Howell · University Of Connecticut Storrs · R01 · FY2021 · GM

HIGH-RESOLUTION IMAGING OF OCULAR MELANOMA AND RETINA

$518,503
University Of California San Diego · R01 · FY2002 · EY

Defining Mechanisms of Pathological Trans-Lesion Synthesis During Carcinogenesis

$518,457
Cyrus Vaziri · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA

Defining Mechanisms of Pathological Trans-Lesion Synthesis During Carcinogenesis

$518,457
Cyrus Vaziri · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA

Defining Mechanisms of Pathological Trans-Lesion Synthesis During Carcinogenesis

$518,457
Cyrus Vaziri · Univ Of North Carolina Chapel Hill · R01 · FY2018 · CA

The Fibrosis-Lymphedema Continuum in Head and Neck Cancer

$518,453
Sheila H Ridner · Vanderbilt University · R01 · FY2010 · CA

Localized immunotherapy using alum-binding therapeutics

$518,397
Darrell J Irvine · Massachusetts Institute Of Technology · R01 · FY2023 · EB

Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma

$518,339
Devanand Sarkar · Virginia Commonwealth University · R01 · FY2020 · CA

(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity

$518,165
Nir Hacohen · Broad Institute, Inc. · R01 · FY2017 · CA